公开(公告)号：US20230054250A1

公开(公告)日：2023-02-23

申请号：US17792499

申请日：2021-01-14

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

发明人： Yong GAN ,  Shiyan GUO ,  Yinyin SUN

IPC分类号： A61K9/127 ,  A61K31/167 ,  A61K31/277 ,  A61K31/5415 ,  A61K31/4748 ,  A61K31/445 ,  A61K31/138 ,  A61K31/475 ,  A61K31/4365 ,  A61K31/245 ,  A61K31/366 ,  A61K31/4422 ,  A61K47/10 ,  A61K47/24 ,  A61K47/14 ,  A61K47/44 ,  A61K47/28 ,  A61K9/00

摘要： A non-aqueous sustained release drug delivery system, which contains, based on the total weight of the sustained release drug delivery system, about 0.1-20% of an active agent, about 0.5-50% of a drug solvent, about 1-98% of a drug sustained release agent, about 0.1-85% of a drug solubilizer, about 0.1-10% of an efficacy enhancer, about 0-1% of an antioxidant, and about 0-8% of an acid-base regulator. The non-aqueous sustained release drug delivery system can yield an improved sustained release effect, improve bioavailability, and enhance the therapeutic effect.

公开(公告)号：US20230080811A1

公开(公告)日：2023-03-16

申请号：US17792474

申请日：2021-01-14

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

发明人： Yong GAN ,  Shiyan GUO ,  Yinyin SUN ,  Quanlei ZHU

IPC分类号： A61K47/24 ,  A61K31/445 ,  A61K47/44 ,  A61K47/12 ,  A61K9/08 ,  A61P23/02

摘要： Provided are a long-acting ropivacaine pharmaceutical composition, a preparation method therefor and use thereof. The pharmaceutical composition comprises: ropivacaine; a pharmaceutical solvent; a pharmaceutical phospholipid; a pharmaceutical oil; and an efficacy enhancer, an optional antioxidant and an optional acid-base regulator. The pharmaceutical composition has a controllable release behavior and a sustained release effect, can significantly reduce the peak plasma concentration of the drug, maintain a stable plasma concentration in the body, prolong the effective treatment time, reduce the effective therapeutic dose, improve the utilization of the drug, and reduce the risk of neurotoxicity. The pharmaceutical composition has a long-acting analgesic effect and can be used for pain treatment.

公开(公告)号：US20180133215A1

公开(公告)日：2018-05-17

申请号：US15574557

申请日：2016-05-13

申请人： SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES ,  Shanghai Acebright Pharmaceuticals Co., Ltd.

发明人： Shiyan GUO ,  Yong GAN ,  Ao ZHANG ,  Zehong MIAO ,  Li GAO ,  Jian DING

IPC分类号： A61K31/502 ,  A61K47/40 ,  A61K47/38 ,  A61K47/34 ,  A61K47/32 ,  A61K9/48 ,  A61K9/28 ,  A61P35/00

CPC分类号： A61K31/502 ,  A61K9/08 ,  A61K9/10 ,  A61K9/146 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/28 ,  A61K9/4858 ,  A61K9/4866 ,  A61K47/10 ,  A61K47/32 ,  A61K47/34 ,  A61K47/38 ,  A61K47/40 ,  A61P35/00

摘要： Disclosed is an SOMCL-9112 solid dispersion. The SOMCL-9112 solid dispersion is characterized by being prepared from the following raw materials in percentage by weight: 5 percent to 60 percent of SOMCL-9112, 5 percent to 90 percent of pharmaceutically acceptable matrix polymer, 0 percent to 20 percent of surfactant, 0 percent to 20 percent of flow aid and 0 percent to 20 percent of plasticizer. Also disclosed are a preparation method of the SOMCL-9112 solid dispersion, a solid medicinal preparation containing the solid dispersion and application of the solid dispersion for preparing a medicine for treating cancer.